CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.

Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana is offering a CAR-T cell-based immunotherapy, which genetically ...

Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.“It is quite ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...

Researchers at the University of Wisconsin School of Veterinary Medicine have identified a possible way to make longer ...